LEIDEN, The Netherlands,
Aug. 14, 2023 /PRNewswire/ --
Pharming Group N.V. ("Pharming" or "the Company") (Euronext:
PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General
Meeting of Shareholders (EGM) on Monday,
September 25, 2023 at 14:00
CEST. The Notice to Convene, Explanatory Notes, Voting
information, meeting documents and Form of Proxy can be found on
the Company's website under Investors/Shareholder Meetings.
The EGM is convened for the appointment of Dr. Richard Peters as Non-Executive Director for a
period of four years, based on a binding nomination by the Board of
Directors. Dr. Peters will become the new Chair of the Board as
successor to Mr. Paul Sekhri,
subject to (and therefore effective as of) his appointment as
Non-Executive Director at the EGM.
The agenda further includes the proposal to approve, by way of a
supplement to the current Remuneration Policy for the Board of
Directors, an increase in the annual fee payable to the Chair of
the Board of Directors.
The EGM will be held as a physical meeting at Pharming's office
at Vondellaan 47 in Leiden, the
Netherlands. Our shareholders are invited to attend the EGM
in person or to follow the meeting through our live webcast.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is
a global biopharmaceutical company dedicated to transforming the
lives of patients with rare, debilitating, and life-threatening
diseases. Pharming is commercializing and developing an innovative
portfolio of protein replacement therapies and precision medicines,
including small molecules, biologics, and gene therapies that are
in early to late-stage development. Pharming is headquartered in
Leiden, Netherlands, and has
employees around the globe who serve patients in over 30 markets in
North America, Europe, the Middle
East, Africa, and
Asia-Pacific.
For more information, visit www.pharming.com and find us on
LinkedIn.
Inside Information
This press release relates to the disclosure of information that
qualifies, or may have qualified, as inside information within the
meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact:
Pharming Group, Leiden, The
Netherlands
Michael Levitan, VP Investor Relations & Corporate
Communications
T: +1 (908) 705 1696
Heather Robertson, Investor
Relations & Corporate Communications Manager
E: investor@pharming.com
FTI Consulting, London,
UK
Victoria Foster
Mitchell/Alex
Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon
Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Logo -
https://mma.prnewswire.com/media/2074393/Pharming_Group_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/pharming-group-to-convene-extraordinary-general-meeting-of-shareholders-301899286.html
